cimetidine has been researched along with u-50488 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
| Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
| Belyakov, S; Dambrova, M; Kazoka, H; Kuznecovs, J; Lebedev, A; Liepinsh, E; Mishnev, A; Orlova, N; Ponomaryov, Y; Vavers, E; Veinberg, G; Vikainis, S; Vilskersts, R; Vorona, M; Zvejniece, L | 1 |
| Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
| Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
| Abdel-Hamid, MK; Andersson, S; Chau, N; Daniel, JA; Deane, FM; Hill, TA; McCluskey, A; Odell, LR; Robinson, PJ; Sakoff, JA; Young, KA | 1 |
| Chen, Y; Hough, LB; Leurs, R; Menge, WM; Nalwalk, JW; Pintar, JE; Schuller, A; Timmerman, H; Zhang, J; Zhu, Y | 1 |
9 other study(ies) available for cimetidine and u-50488
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Topics: Acetamides; Allosteric Regulation; Animals; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Stereoisomerism; Structure-Activity Relationship | 2013 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.
Topics: Binding, Competitive; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line, Tumor; Drug Screening Assays, Antitumor; Dynamin I; Enzyme Inhibitors; Humans; Mass Spectrometry; Pleckstrin Homology Domains; Proton Magnetic Resonance Spectroscopy; Pyrimidines | 2017 |
Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesia; Analgesics, Non-Narcotic; Animals; Cerebral Ventricles; Cimetidine; Enkephalin, D-Penicillamine (2,5)-; Exons; Female; Gene Expression Regulation; Genotype; Injections, Intraventricular; Male; Mice; Mice, Knockout; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2000 |